Programmed death-ligand 1 and programmed death-ligand 2 expression can affect prognosis in extramammary paget's disease

6Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: Extramammary Paget's disease (EMPD) is a type of carcinoma that usually progresses slowly but may cause metastasis and subsequent death of patients. We investigated the relationship between the expression of programmed death-ligand 1 (PD-L1)/programmed deathligand 2 (PD-L2) and stromal CD8+ tumor-infiltrating lymphocytes (TILs) in EMPD and clinicopathological findings, including prognosis. Materials and Methods: We examined 47 cases of EMPD and performed immunohistochemical staining of formalin-fixed paraffin-embedded fullface sections. Results: PD-L1 expression in tumor cells was observed in 13 cases (27.7%) while PD-L2 expression was observed in 21 cases (44.7%). The cumulative postoperative recurrence-free rate in the group with positivity for PD-L1 and/or PD-L2 with a low CD8+ TIL count was significantly lower than that of the corresponding group with a high CD8+ TIL count and of the PD-L1- and PD-L2-negative group (p=0.026). Conclusion: The expression of PD-L1/PD-L2 in tumor cells was shown to be a factor for poor prognosis.

Cite

CITATION STYLE

APA

KAWAGUCHI, A., AKIBA, J., KONDO, R., SADASHIMA, E., OGASAWARA, S., NAITO, Y., … YANO, H. (2021). Programmed death-ligand 1 and programmed death-ligand 2 expression can affect prognosis in extramammary paget’s disease. Anticancer Research, 41(1), 219–226. https://doi.org/10.21873/anticanres.14768

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free